Biotech Values

[AlpineBV_Miller]

Yes, but I doubt Dendreon will get there unless this issue persists into 2012 with little improvement. The problem is I'm not sure whether a $75,000 or $60,000 or even $45,000 price point will make a ton of difference to this cash flow problem. You'd get a bit of a boost simply because the practice could fit single-digit more patients per month into their existing cash flow/LOC situation, but then you'd be stuck right back at the same slow growth curve after a couple of months.

Dendreon will want to work through several ideas and strategies before resorting to a price cut. It chould be said I doubt urologists will WANT a price cut because it reduces the amount they get paid for Provenge.